• 1
    Safdar A, Hanna HA, Boktour M, et al. Impact of high-dose granulocyte transfusions in cancer patients with candidemia. Cancer. 2004; 101: 28592865 [Epub ahead of print].
  • 2
    Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002; 34: 909917.
  • 3
    Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine (Baltimore). 1993; 72: 7889.
  • 4
    Wald A, Leisenring W, van Burik JAH, Bowden RA. Epidemiology of Aspergillus infection in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997; 175: 14591466.
  • 5
    Denning DW. Invasive aspergillosis in immunocompromised patients. Curr Opin Infect Dis. 1994; 7: 456462.
  • 6
    Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001; 32: 358366.
  • 7
    Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996; 23: 608615.
  • 8
    Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347: 408415.
  • 9
    Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus: observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest. 1982; 69: 617631.
  • 10
    Cassatella MA, Cappelli R, Della Bianca V, Grzeskowiak M, Dusi S, Berton G. Interferon-gamma activities human neutrophil oxygen metabolism and exocytosis. Immunology. 1988; 63: 499506.
  • 11
    Shalaby MR, Aggarwal BB, Rinderknecht E, Svendersky LP, Finkle BS, Palladino MA. Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factor. J Immunol. 1985; 135: 20692073.
  • 12
    Brummer E, Kamberi M, Stevens DA. Regulation by granulocyte-macrophage colony-stimulating factor and/or steroids given in vitro of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to Aspergillus conidia. J Infect Dis. 2003; 187: 705709.
  • 13
    Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun. 1993; 61: 11851193.
  • 14
    Puccetti P, Romani L, Bistoni F. A TH1-TH2-like switch in candidiasis: new perspective for therapy. Trends Microbiol. 1995; 3: 237240.
  • 15
    Romani L, Puccetti P, Bistoni F. Biological role of helper T-cell subsets in candidiasis. Chem Immunol. 1996; 63: 113137.
  • 16
    Mencacci A, Perruccio K, Bacci A, et al. Defective antifungal T-helper 1 (TH1) immunity in a murine model of allogeneic T-cell-dependent bone marrow transplantation and its restoration by treatment with TH2 cytokine antagonists. Blood. 2001; 97: 14831490.
  • 17
    Reisner Y, Itzicovitch I, Meshorer A, Sharon N. Hemopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins. Proc Natl Acad Sci USA. 1978; 75: 29332936.
  • 18
    Bachar-Lustig E, Rachamin N, Hong-Wei L, Lan F, Reisner Y. Megadose of T cell-depleted bone marrow overcome MHC barriers in sublethally irradiated mice. Nat Med. 1995; 12: 12681273.
  • 19
    Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2002; 30: 899903.
  • 20
    Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor alpha blockade for the treatment of acute GVHD. Blood. 2004; 104: 649654.
  • 21
    Brok HPM, Heidt PJ, van der Meide PH, Zurcher C, Vossen JM. Interferon-γ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol. 1993; 151: 64516459.
  • 22
    Brok HP, Vossen JM, Heidt PJ. IFN-gamma-mediated prevention of graft-versus-host diseases: pharmacodynamic studies and influence on proliferation capacity of chimeric spleen cells. Bone Marrow Transplant. 1998; 22: 10051010.
  • 23
    Sykes M, Romick ML, Sachs DH. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci USA. 1990; 87: 56335637.
  • 24
    Sykes M, Szot GL, Nguyen PL, Pearson DA. Interleukin-12 inhibits murine graft-versus-host disease. Blood. 1995; 86: 24292438.
  • 25
    Yang YG, Sergio JJ, Pearson DA, Szot GL, Shimizu A, Sykes M. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic DC8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood. 1997; 90: 46514660.
  • 26
    Yang YG, Dey BR, Sergio JJ, Pearson DA, Sykes M. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest. 1998; 102: 21262135.
  • 27
    Yang YG, Sykes M. The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD. Leuk Lymphoma. 1999; 33: 409420.
  • 28
    Murphy WJ, Welniak LA, Taub DD, et al. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest. 1998; 102: 17421748.
  • 29
    Reddy P, Teshima T, Kukuruga M, et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med. 2001; 194: 14331440.
  • 30
    Kozlowski T, Sablinski T, Basker M, et al. Decreased graft-versus-host disease after haplotype mismatched bone marrow allografts in miniature swine following interleukin-2 treatment. Bone Marrow Transplant. 2000; 25: 4752.
  • 31
    Tarrand JJ, Lichterfeld M, Warraich I, et al. Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol. 2003; 119: 854858.
  • 32
    Przepiorka D, Ippoliti C, Khouri I, et al. Tacrolimus and mini-dose methotrexate for prevention of acute graft-vs-host disease after matched unrelated donor marrow transplantation. Blood. 1996; 88: 43834389.
  • 33
    Przepiorka D, Saliba R, Cleary K, et al. Tacrolimus dose not abrogate the increased risk of acute graft-vs-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant. 2000; 6: 190195.
  • 34
    Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002; 34: 714.
  • 35
    Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant. 2001; 28: 873878.
  • 36
    Safdar A, Singhal S, Mehta J. Clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993–2001). Cancer. 2004; 100: 24562461.
  • 37
    Chan GW, Gorgun G, Miller KB, Foss FM. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood Marrow Transplant. 2003; 9: 170176.
  • 38
    Rus V, Svetic A, Nguyen P, et al. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease: regulatory role of donor CD8+ T cells. J Immunol. 1995; 155: 23962406.
  • 39
    Miura Y, Thoburn CJ, Bright EC, Chen W, Nakao S, Hess AD. Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon γ may be critical mediators for the development of autologous GVHD. Blood. 2002; 100: 26502658.
  • 40
    Ferrara JL, Cooke K, Pan L, Krenger W. The immunopathophysiology of acute graft-versus-host disease. Stem Cells. 1996; 14: 473489.
  • 41
    Krenger W, Ferrara J. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res. 1996; 15: 5073.
  • 42
    Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest. 2000; 105: 12891298.
  • 43
    Blazar BR, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow cells. Blood. 1995; 85: 842851.
  • 44
    Krenger W, Snyder K, Smith S, Ferrara JLM. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation. 1994; 58: 12511257.
  • 45
    Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis. 1994; 18: 273284.
  • 46
    Antin JH, Ferrara JLM. Cytokine dysregulation in acute graft-versus-host disease. Blood. 1992; 80: 29642968.
  • 47
    Liu Y, Janeway CA Jr. Interferon gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance. J Exp Med. 1990; 172: 17351739.
  • 48
    Strom T, Roy-Chaudhury P, Manfro R, et al. The Th1/Th2 paradigm and allograft response. Curr Opin Immunol. 1996; 8: 688702.
  • 49
    Murphy WJ, Longo DL. The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation. Immunol Rev. 1997; 157: 167176.